MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajhg.2020.06.011

Медицинская библиотека · American journal of human genetics · 2020

Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypically Diverse Dominant Maculopathy.

Sinha Divya, Steyer Benjamin, Shahi Pawan K, Mueller Katherine P, Valiauga Rasa, Edwards Kimberly L, Bacig Cole, Steltzer Stephanie S, Srinivasan Sandhya, Abdeen Amr, Cory Evan, Periyasamy Viswesh, Siahpirani Alireza Fotuhi, Stone Edwin M, Tucker Budd A, Roy Sushmita, Pattnaik Bikash R, Saha Krishanu, Gamm David M

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод пока не подготовлен

Аннотация

Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentation to treat Best disease, a dominant macular dystrophy caused by over 200 missense mutations in BEST1. Gene augmentation in iPSC-RPE fully restored BEST1 calcium-activated chloride channel activity and improved rhodopsin degradation in an iPSC-RPE model of recessive bestrophinopathy as well as in two models of dominant Best disease caused by different mutations in regions encoding ion-binding domains. A third dominant Best disease iPSC-RPE model did not respond to gene augmentation, but showed normalization of BEST1 channel activity following CRISPR-Cas9 editing of the mutant allele. We then subjected all three dominant Best disease iPSC-RPE models to gene editing, which produced premature stop codons specifically within the mutant BEST1 alleles. Single-cell profiling demonstrated no adverse perturbation of retinal pigment epithelium (RPE) transcriptional programs in any model, although off-target analysis detected a silent genomic alteration in one model. These results suggest that gene augmentation is a viable first-line approach for some individuals with dominant Best disease and that non-responders are candidates for alternate approaches such as gene editing. However, testing gene editing strategies for on-target efficiency and off-target events using personalized iPSC-RPE model systems is warranted. In summary, personalized iPSC-RPE models can be used to select among a growing list of gene therapy options to maximize safety and efficacy while minimizing time and cost. Similar scenarios likely exist for other genotypically diverse channelopathies, expanding the therapeutic landscape for affected individuals.

Для цитирования: Sinha Divya, Steyer Benjamin, Shahi Pawan K, Mueller Katherine P, Valiauga Rasa, Edwards Kimberly L, Bacig Cole, Steltzer Stephanie S, Srinivasan Sandhya, Abdeen Amr, Cory Evan, Periyasamy Viswesh, Siahpirani Alireza Fotuhi, Stone Edwin M, Tucker Budd A, Roy Sushmita, Pattnaik Bikash R, Saha Krishanu, Gamm David M. Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypically Diverse Dominant Maculopathy.. American journal of human genetics. 2020. DOI: 10.1016/j.ajhg.2020.06.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.